CDK4/6 Inhibitors in Breast Cancer—Who Should Receive Them?

TL;DR

This paper explores how CDK4/6 inhibitors can be better targeted in breast cancer treatment, especially for patients with specific genetic changes.

Contribution

The study identifies that loss of the NF1 tumor suppressor increases sensitivity to CDK4/6 inhibitors in breast cancer.

Findings

NF1 loss makes tumors more reliant on CDK4/6 activity for survival.

CDK4/6 inhibition is more effective in tumors with NF1 loss when combined with endocrine therapy.

Abstract

More than 70% of breast cancers are estrogen receptor-positive (ER+). Endocrine therapy that blocks estrogen signaling remains the cornerstone of treatment, yet relapses continue to affect many patients. Cyclin-dependent kinases 4 and 6 (CDK4/6) regulate the G1-S phase transition in the cell cycle, and pharmacological inhibition of this pathway has been successfully leveraged to reduce recurrence. CDK4/6 inhibitors combined with endocrine therapy are now the standard of care, although determining the optimal patient population for treatment remains a key challenge. A newly published study provides important insight, showing that loss of the NF1/neurofibromin tumor suppressor confers greater sensitivity to CDK4/6 inhibition, as these tumors rely heavily on CDK4/6 activity for survival under endocrine therapy.

Figures